Cooper's 14% Drop Asks One Question: Overhang or Demand?

CooperCompanies fell about 14% in a single day and is down more than a third for the year, a violent move for a medical-device maker that usually drifts by a couple of percent. The trigger was a fiscal third-quarter report that was mixed on the surface — adjusted earnings beat, revenue slightly missed — but it was the forward-looking parts that did the damage: a fourth-quarter outlook well below consensus, and the news that a long-awaited review of the CooperSurgical division would end without a sale.

The headline reads like a growth story breaking. The question that actually separates opportunity from value trap is narrower. Cooper's own management says the shortfall is not weak demand but a deliberate, accelerated reduction of inventory sitting in its U.S. distribution channel — a correction it says was roughly half finished by the end of the quarter and due to clear by the fiscal year-end. Underlying U.S. consumption at CooperVision, they argue, kept growing at a mid-single-digit rate while the company worked down stock that distributors had overbought ahead of price increases, customer consolidation, and new contract wins.

The numbers line up with that reading. Reported third-quarter revenue rose about 1% to $1.066 billion. CooperVision was essentially flat at $717 million — the drag is exactly where the destocking happened. CooperSurgical, untouched by the inventory issue, grew 3% organically to $349 million, led by a 5% gain in fertility products. The soft guidance follows the same logic: fourth-quarter organic revenue guided to fall up to 2% or come in flat, the full weight of the remaining destocking landing in the current quarter even as CooperSurgical is guided up 4% to 6%.

A value investor tests this story against the balance sheet before accepting it, because if the inventory explanation is wrong, the low multiple is a warning rather than a bargain. The cash flows here are strong. Cooper generated a record $273 million free cash flow in the quarter and $528 million year to date, up 86% from a year ago. Net debt is about $2.4 billion against roughly $8 billion of equity, a conservative setup for a company of this size. And because Cooper pays no dividend, the buyback is the return channel: it repurchased $339 million of shares in the quarter and expanded its authorization by $1 billion, leaving around $1.5 billion of room.

The second leg of the drop is the CooperSurgical decision, and here the market's disappointment is understandable even if the board's reasoning is its own kind of discipline. Investors had bid the stock on hopes that selling the surgical unit would crystallize value. Instead, the board received significant interest but walked away because offers did not reflect intrinsic value, citing temporary factors: a newly approved competing non-hormonal IUD and settlements tied to fertility litigation. Refusing to sell a business below what it is worth is the standard a value investor would want a board to hold. But the consequence is real: the IUD competition and the litigation stay on the books, and whatever "deal premium" the stock carried is gone.

What the drop leaves you with is a valuation that has stopped demanding much optimism. At about $54, the market cap is roughly $10 billion and the stock trades near its 52-week low, at a bit under 14 times trailing EBITDA and roughly 12 times the reduced full-year earnings guidance of around $4.53 a share. That is a steep discount to the premium multiple this quality compounder has historically commanded, priced for the inventory correction to be a real cost, not a rounding error.

The honest caveat is that the year ahead is not free of drag. The non-GAAP tax rate is scheduled to step up to roughly 17.5% next fiscal year from about 15.5%, and the fourth quarter — the quarter where the entire CooperVision decline is loaded — is the window in which the inventory story is tested in full. If management's explanation holds, the buyer here is getting a leading contact-lens franchise with a clean balance sheet and a growing consumer franchise at a discount to its normal multiple, with the overhang set to clear. If destocking turns out to be a euphemism for demand that is actually fading, today's low multiple can still get cheaper. The stock no longer requires you to believe in growth — only to believe that the inventory story is true and temporary. That is the bet the price is asking you to make, and it is worth knowing which side you are on before the fourth quarter answers it.